Melanoma-associated antigen 3 peptide presented by MHC class I (MAGE-A3 peptide (presented by MHC class I))

The MAGE-A3 peptide presented by MHC class I is an antigenic fragment from the MAGE-A3 protein—a member of the cancer/testis antigen family, usually restricted to germ cells but aberrantly expressed in various cancers[3][6][1]. When fragments of MAGE-A3 are processed and loaded onto MHC class I molecules by malignant cells, they become a target for cytotoxic T cells, which can recognize and kill cancer cells through immunological mechanisms. Therapeutic strategies include vaccines (mRNA or recombinant protein) and adoptive cell therapy using engineered T-cell receptors (TCRs) specific for MAGE-A3 peptides[2][3][1]. Despite its promise as a highly tumor-specific target, clinical efficacy has been challenged by immunological heterogeneity, tumor escape mechanisms, and sometimes severe adverse effects caused by off-target immune reactions[1][5][8]. MAGE-A3 mRNA and protein levels are also explored as diagnostic and prognostic biomarkers in cancers such as lung adenocarcinoma (LUAD), non-small cell lung cancer (NSCLC), and melanoma[4][1].

Other names

MAGEA3 peptideMAGE-A3/HLA class I peptidecancer/testis antigen MAGE-A3 peptide

Activation of cytotoxic CD8+ T lymphocytes by presentation of MAGE-A3-derived peptides on MHC class I molecules, leading to targeted lysis of tumor cells expressing the antigen[3][7]; Active immunization through peptide or mRNA vaccines, generating T-cell responses against tumor cells[2][1]